Introduction
The direct injection of plasmid DNA into skeletal muscle is a simple method of achieving gene transfer for the purposes of gene therapy. However, plasmid gene transfer is hampered by poor transfection efficiencies in comparison with viral vectors, with the earliest reports of direct plasmid gene transfer transfecting only approximately 1% of muscle fibres. 1, 2 Since these initial reports many factors have been investigated as methods of improving plasmid gene transfer including the age and sex of animals, plasmid design, the solute used and the injection technique. These methods have met with some success; [3] [4] [5] [6] [7] however, none of these methods has resulted in the dramatic improvement that has been achieved since the inception of electrotransfer-mediated gene delivery. [8] [9] [10] Electrotransfer-mediated plasmid gene therapy is being investigated for a variety of nonmuscle and muscle diseases, including muscular dystrophies such as Duchenne's muscular dystrophy (DMD) and congenital muscular dystrophy (CMD). 11 For any gene therapy protocol for DMD to be clinically relevant, the number of transfected fibres within a muscle is critical. However, the process of electrotransfer has been demonstrated to induce muscle damage. 8, 12, 13 The progressive degeneration of the muscle in DMD dictates that the number of myofibres with a given muscle is reduced. It is therefore essential along with maximal transfection efficiency, that electrotransfer protocols ensure the maximal survival of muscle fibres which, because of the progression of the disease, will have limited regenerative capacity.
Skeletal muscle contains a number of potential 'barriers' comprised of extracellular matrix (ECM) that may be responsible for the poor efficiency of plasmid transfer into the muscle. There are three different tiers of potential ECM barrier. Individual myofibres are surrounded by a layer of ECM known as the endomysium; myofibres are then organised into bundles or fascicles surrounded by ECM known as the perimysium; and the entire muscle is surrounded by a further layer of ECM, the epimysium. In addition, a number of muscles, including the tibialis anterior (TA), contain a central tendon that runs through the length of the muscle, thus potentially acting as a further barrier. There is evidence to suggest that following simple direct injection of plasmid DNA into skeletal muscle there is widespread distribution of the plasmid throughout the muscle. 3 However, what is not clear is the access of the plasmid to the plasma membrane, which may be impeded because of the presence of connective tissue.
It has previously been demonstrated that the pretreatment of skeletal muscle with bovine hyaluronidase, prior to plasmid electrotransfer, can significantly improve transfection efficiencies compared to electrotransfer alone, 12, 14 and we have previously published data demonstrating that the pretreatment of muscle with hyaluronidase can reduced the damage associated with electrotransfer in nondystrophic muscle. 12 The improvements in transfection efficiency achieved with hyaluronidase and electrotransfer may be a result of improved accessibility of the plasmid DNA to the muscle fibre surface. However, one of the characteristic pathological changes within the muscles of dystrophic patients, and to a lesser extent in the mouse model of DMD (mdx mouse), is the replacement of muscle fibres with increased levels of ECM and fatty deposits. This increase in levels of connective tissue may pose a further limitation to the electrotransfer of plasmid DNA in dystrophic muscle. In addition, muscle fibres within dystrophic muscle undergo rounds of degeneration and regeneration. This is also a variable that may affect the efficiency of electrotransfer in dystrophic muscle. The current paper investigates the use of an optimised hyaluronidase and electrotransfer protocol in muscle that has been artificially regenerated and in the dystrophic muscle of the mdx mouse, in terms of transfection efficiency, total b-galactosidase expression and muscle damage. Factors such as age and sex of mice, which are known to affect transfection efficiency following direct injection of plasmid DNA are also considered.
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Results
Electrotransfer in artificially induced regenerating muscle
To assess the effect of muscle regeneration on the efficiency of electrotransfer, the percentage area of muscle transfected with pCMVb was compared in normal skeletal muscle and artificially regenerating muscle of male 6-week-old F1 mice following plasmid DNA electrotransfer with hyaluronidase pretreatment. Transverse muscle sections were stained for b-galactosidase expression and were analysed to establish the maximum area transfected within any one muscle.
Extremely high transfection efficiencies were achieved in nonregenerating muscle following hyaluronidase and electrotransfer, and were significantly higher than in artificially induced regenerating muscle. Table 1 shows individual transfected areas and the mean transfected area of each group. Statistical analysis by paired t-test showed that a significant difference (P¼0.005) exists between the two groups. Despite the difference between the two groups, levels of transfection obtained in regenerating muscle were also extremely efficient.
Distribution of positive fibres in nonregenerating muscle was very widespread through superficial and deep regions of the muscle, with 97.5% of one muscle (transverse muscle section) staining positive for bgalactosidase. Distribution of positive fibres in regenerating muscle was also extensive through both superficial and deep muscle (data not shown). Spread of positive fibres was not limited by the presence of the central tendon in either of the experimental groups, in contrast to previously published observations. 12 The results of this experiment showed that it was possible to efficiently transfect regenerating muscle fibres by electrotransfer.
Electrotransfer in dystrophic and nondystrophic muscle: effect of connective tissue and age
To assess the effect of age and fibrosis on the efficiency of electrotransfer, total levels of b-galactosidase expression and transfection efficiencies were analysed following plasmid DNA electrotransfer in 7-week-old C57BL/10 (n¼8) and mdx mice (n¼6) and 20-21-week-old C57BL/ 10 (n¼8) and mdx mice (n¼9). All mice were female.
Connective tissue was assessed in the different experimental groups, by staining with picric acid and sirius red. Qualitatively, no significant difference was observed in the amount of connective tissue staining between 7-and 20-week-old C57BL/10 mice. However, an increase in the amount of connective tissue was observed in dystrophic muscle taken from the 7-week old mice compared to C57BL/10. A further increase in the amount of connective tissue staining was seen in the 21-week-old mdx mice compared to the 7-week-old mdx mice ( Figure 1) .
The electrotransfer of CMVb in both normal and dystrophic muscle resulted in high levels of b-galactosidase expression as determined by ELISA (Figure 2a ). There were no significant differences in levels of transgene expression between any of the groups analysed. Consistent with the ELISA results, very high transfection efficiencies were observed in C57BL/10 and mdx mice of both ages. No decline in transfection efficiency was observed in association with increased levels of connective tissue in dystrophic muscle or with increased age of the mice, with 40%75 transfection of muscle fibres achieved in 21-week-old mdx mice compared to 34%74.8 in age-matched C57BL/10 mice (Figure 2b ).
Pathology associated with dystrophic muscle was apparent in both age groups of mdx mice. Centrally nucleated fibres and fibres of nonuniform diameter were seen in both groups, indicative of mdx pathology. Microscopic analysis indicated that fibre diameter did not appear to affect electrotransfer, with fibres of many diameters being transfected. Some variation in transfection efficiency was seen within the experimental groups. Variation in transfection efficiency did not appear to be related to muscle damage, although the degree of damage did vary both within and between groups. Very little inflammation was seen in the muscles of 7-week-old mdx mice, with larger inflammatory lesions observed in the older mdx mice. Little damage was observed within the muscles of 7-week-old C57BL/10 mice. In comparison, 20-week-old C57BL/10 mice showed more variation in the levels of damage following electrotransfer ( Figure 3) .
The spatial distribution of transfected muscle fibres was consistent between groups. Occasionally, very high transfection efficiencies were observed and transfected muscle fibres were widespread throughout both the superficial and deep portions of the muscle. However, in general, the vast majority of the transfected fibres were seen within the superficial region of the muscle, and occasionally transfected fibres were observed along the peripheral edge of the deep part of the muscle ( Figure 4 ). The distal-proximal distribution of b-galactosidase expression was similar in all of the groups, with bgalactosidase activity present along the length of the muscle (data not shown).
Hyaluronidase titration in the mdx mouse
In order to assess the effect of increasing hyaluronidase concentration on the efficiency of electrotransfer in the mdx mouse, groups of 26 to 29-week-old female mdx mice (n¼4) were pretreated with either 10, 40, 70 or 100 U of hyaluronidase in the left TA, while the right TA received no treatment. Both the untreated and treated TA muscles were injected with plasmid DNA followed by electrotransfer. TA muscles treated with both hyaluronidase and electrotransfer showed a significant improvement in transfection efficiency when compared to nonhyaluronidase-treated control muscle (means of 5-10% of transverse cross-sectional area compared to 30-40%) (Po0.001). No significant differences were observed in the transfection efficiency in groups of mice that had been treated with 10, 40, 70 or 100 U of hyaluronidase ( Figure 5 ). Increasing the concentration of hyaluronidase injected had no effect on the distribution of the transfected fibres, which were mainly limited to the superficial muscle and appeared to be limited by the presence of the central tendon. Areas of damage and inflammation were observed within each of the 
Does sex of mice affect efficiency of electrotransfer?
The sex of the mice used in gene transfer experiments has also been shown to have an effect on the number of transfected fibres achieved following direct injection of plasmid DNA in skeletal muscle. 6 In order to assess the effect of the sex of mice on efficiency of electrotransfer the TA muscles of groups of 20-week-old male and female mdx mice (n¼8) were pretreated with either 10 or 40 U of hyaluronidase, followed by plasmid electrotransfer.
There was no significant difference in the percentage area of muscle expressing b-galactosidase following electrotransfer between male and female mice treated with 10 U of hyaluronidase or between male and female mice that had been treated with 40 U of hyaluronidase (Figure 6a ). Analysis of total levels of b-galactosidase expression supports these findings (Figure 6b ). Histological analysis of b-galactosidase-positive fibres in the TA muscle showed no difference in the spatial distribution of positive fibres between male and female mice, or between groups of mice following treatment with either 10 or 40 U of hyaluronidase
Electrotransfer of dystrophin plasmid in the mdx mouse
The efficiency of electrotransfer of dystrophin plasmids was analysed in mdx mice (11 to 14-weeks old) following the electrotransfer of plasmid DNA expressing either mouse full-length dystrophin or human mini dystrophin. Efficient gene transfer was achieved with both dystro- (Figure 7) . Expression of full-length mouse dystrophin was found to be maintained up to 8 weeks postinjection, which was the last time point examined.
Discussion
Plasmid DNA has a number of advantages over viral vectors as a vector for gene therapy. New constructs can be made readily with no apparent constraint on insert size, which is a substantial problem with viral vectors such as adeno-associated virus (AAV). Plasmid DNA can be produced and validated on a pharmaceutical scale and has been shown to have a good safety record in genetic vaccination clinical trials. Importantly, plasmid DNA has a significant advantage in that repeated administration is possible in immunocompetent animals. In contrast, vector specific neutralising antibodies and cytotoxic immune responses seriously limit the potential for the readministration of viral vectors. 16, 17 The major limitation of plasmid DNA is the relatively low efficiency of transfection in comparison to viral vectors although recently significant steps have been made towards improving transfection efficiency. The advent of electrotransfer has routinely increased reporter 
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H Gollins et al protein expression levels by 10 to 500-fold. 8, 10, 13, 18 Similarly, reports have shown that percentage of transfected fibres increases from 1%, following the direct injection of plasmid DNA, to more than 10% 8,13 following electrotransfer. Recently, further improvements have been reported by Vilquin et al, 11 who achieved 37% transfection following multiple site injections and electrotransfer. In addition, it has also been shown that pretreatment of the muscle with hyaluronidase followed by electrotransfer can result in significant improvements in plasmid gene transfer, 12, 14 and that 50% levels of transfection in nondystrophic muscle can routinely be achieved in our hands. 12 The results presented here demonstrate that very efficient plasmid gene transfer can be achieved with a single injection into the dystrophic muscle of the mdx mouse mediated by hyaluronidase and electrotransfer, despite the presence of increased levels of connective tissue within the muscle.
We demonstrate that the presence of increased levels of fibrotic tissue within the mdx muscle does not cause a significant difference in the efficiency of transfection as compared to age-matched C57BL/10 mice. This strongly suggests that the presence of fibrotic material within the muscle does not hamper electrotransfer since we routinely achieved efficiencies of approximately 40% in dystrophic muscle. This is different from the work of Vilquin et al, who described transfection efficiencies of up to 40% in normal muscle and only 20% in the mdx mouse following multiple injections. In the current study, transfection efficiency and distribution of positive fibres could not be further improved by increasing the concentration of hyaluronidase injected. However, the extent of fibrosis in the mdx mouse does not parallel the clinical situation in that the mdx mouse has a greater regenerative capacity than DMD patients and shows substantially less replacement of muscle fibres with fibrotic and adipose tissue. 19 Therefore, it is a possibility that much higher levels of connective tissue seen in muscular dystrophy patients may hinder the electrotransfer process and that current protocols will have to be adapted further.
The electrotransfer process has been demonstrated to be associated with muscle damage. 8, 12, 13 Recently, it has been reported that the pretreatment of skeletal muscle with hyaluronidase, and the reduced voltage that this allows, results in decreased muscle damage. Histological analysis in the current study demonstrated that this damage was not exacerbated in the dystrophic phenotype.
Following the direct injection of plasmid DNA expressing a reporter gene into skeletal muscle, both Plasmid gene transfer H Gollins et al age and sex of the rodents have been shown to play an important role in transfection efficiency. 6, 15 Rapidly growing young male rodents show higher levels of transgene expression and higher numbers of transfected fibres than older animals or age-matched females. We have shown that the use of electrotransfer overcomes age and sex limitations on transfection efficiency. The lack of effect of age and sex on transfection efficiency when using plasmid electrotransfer in comparison to direct injection is likely because of different uptake mechanisms of plasmid DNA. There is increasing evidence to suggest that uptake of plasmid DNA into skeletal muscle following direct injection is carried out by receptormediated endocytosis (RME), 20, 21 whereas electrotransfer of plasmid DNA is dependent on permeabilisation of the cell membrane and the electrophoresis of the DNA across the membrane and into the cell. This difference in the method of entry of plasmid into muscle fibres may explain why hyaluronidase pretreatment improves electrotransfer, but not the direct injection, of plasmid DNA. 12, 14 We speculate that the hyaluronidase pretreatment permeabilises the pericellular matrix of the muscle fibre, thus increasing the effective concentration of plasmid at the membrane leading to increased uptake.
Although electrotransfer with hyaluronidase consistently results in high transfection efficiencies, considerable variation in and between experimental groups can occur. The exact reasons for this variation are unclear. A number of factors are likely to play a role. Firstly, adjustment of field strength for each animal may be important as TA muscles may vary in size. Secondly, exact placement of the needle within a muscle during gene delivery, in relation to the central tendon, may significantly affect the distribution of transfected fibres. Thirdly, orientation of the electrical field is important for electropermeabilization. 22 Electropermeabilization is dependent upon the radius of curvature of the cell and tends to occur more readily at points of the cell that are perpendicular to the electrical field. This effect may explain the reduced transfection efficiency in the muscles that were induced to undergo regeneration in the first experiment, as satellite cells and newly regenerating myotubes will have a substantially different radius of curvature than mature muscle fibres. Differences in the position of the electrodes from animal to animal may also affect the degree of permeabilization that occurs and thus affect transfection efficiency. However, we could not see any clear correlation between fibre size and transfection efficiency. There was particularly marked variation in efficiency between the first (regeneration) experiment and subsequent experiments. We were unable to identify the reason for this difference but possible causes include the strain of mouse (F1 compared to C57BL/10 or mdx) and the plasmid batch that was used. However, we have occasionally observed such large differences within the F1 strain (unpublished observations), and so think that it is unlikely this is a genuine strain effect. Age does not appear to be an important variable as the age was similar between the F1 mice in the first experiment and the younger C57BL/10 and mdx mice in the second experiment. Different batches of plasmid DNA have been implicated as a possible cause of variation in simple injections of naked plasmid DNA. 5 The expression of mini-and full-length dystrophin in skeletal muscle following gene transfer has been shown to protect transfected fibres from degeneration. 1, [23] [24] [25] Data from adenovirus studies suggest that transfection of 40% of myofibres within a muscle is sufficient to recover a mechanical resistance that is comparable to normal muscle, following eccentric contractions. 24 Here we demonstrate that potentially therapeutic levels of gene transfer can be achieved using hyaluronidase and electrotransfer in dystrophic muscle with the reporter plasmid CMVb. However, electrotransfer efficiencies fall when used in association with both full-length and minidystrophin constructs. There are a number of reasons why this may occur. There may be limitations in the detection of dystrophin expression compared to the detection of b-galactosidase. Recent experiments in this group demonstrated that increased detection efficiency of dystrophin with a new antidystrophin antibody (Dys C3750) did not result in the detection of significantly more dystrophin positive fibres (data not shown). Secondly, the process of electrotransfer is dependent on the poration of the cell membrane followed by the electrophoretic movement of the plasmid into the cell cytoplasm. The increased size and electrical charge of the dystrophin plasmids compared to CMVb may affect the efficiency of this process. The effect of plasmid size on efficiency of electrotransfer is currently being investigated by this group.
We have shown that electrotransfer in conjunction with hyaluronidase improves transfection efficiencies within dystrophic muscle to potentially therapeutic levels with a single administration of plasmid DNA. Increases in the levels of ECM have not proved to be an obstacle to the efficiency of electrotransfer, which bodes well for the use of this technique in larger animals where connective tissue barriers have been identified as a major limitation to plasmid gene transfer. 26 These data suggest that electrotransfer-mediated plasmid gene therapy is a real alternative to viral vectors not only for the delivery of systemic proteins, but possibly also for the treatment of muscular dystrophies, although all vector systems are currently unlikely to achieve widespread delivery following simple intramuscular injection when scaling up from small mouse muscles to the much larger human muscles.
Materials and methods
Preparation of plasmid DNA
The plasmids CMVb (7.1 kb), containing the b-galactosidase gene under the control of the cytomegalovirus (CMV) immediate-early promoter (Clontech, Palo Alto, USA), CMVMoDys (16.8 kb), 27 containing mouse fulllength dystrophin under the control of the CMV immediate-early promoter and CBC (12.7 kb) 28 containing, human mini dystrophin under the control of the CMV immediate-early promoter, were grown in XL1Blue (Stratagene, La Jolla, USA) and purified using ENDofree plasmid kits from Qiagen (Crawley, UK). The plasmid preparation contained o0.01 EU/mg endotoxin (lipopolysaccharide) contamination as assessed using Pyrogent 500 turbimetric assay (BioWhittaker, Wokingham, UK).
Intramuscular injection of plasmid DNA
In vivo experiments were carried out on C57BL/ 10 Â CBA/Ca (F1), C57BL/10 and mdx mice (sex and age of animals is specified for each experiment). Animals were housed in a minimal disease facility with food and water ad libitum. Prior to intramuscular injection mice were anaesthised with fentanyl/fluanisone and midazolam (Hypnorm, Janssen Animal Health, High Wycombe, UK and Hypnovel, Roche, Welwyn Garden City, UK, respectively). Tibialis anterior muscles were injected with 10 U (25 ml at 0.4 U/ml) of bovine hyaluronidase (Sigma, Poole, UK) unless otherwise specified. Injections were carried out using a 27-gauge needle in a proximal-todistal direction in the tibialis anterior muscle, as previously described. 7 Two hours post-hyaluronidase injection, plasmid DNA (CMVb at 1 mg/ml or CMVMoDys/CBC at 2 mg/ml) in normal saline was injected percutaneously in the TA muscle. An electrical field was applied to the muscle immediately following plasmid injection. The injection of plasmid DNA and the electrotransfer of plasmid DNA was carried out under isoflurane inhalation anaesthesia. The injected leg was held steady and the 7 mm circular electrodes (BTX, Tweezertrodest, Kramel Biotech, Cramlington, UK) applied to the medial and lateral sides of the lower hind limb with reasonable pressure to maintain contact with the skin surface. Electrode jelly was used on the electrode plates to ensure good electrical contact. A voltage of 175 V/cm was applied in ten 20 ms square wave pulses at 1 Hz using a BTX ECM 830 electroporator. Samples were then collected 7 days after the injection of plasmid DNA.
Control groups were left untreated or the muscles were given a 2-hour pretreatment with 25 ml of normal saline. In specified experiments, regeneration of the TA muscle was induced by injecting a 1.2% barium chloride solution 5 days prior to the electrotransfer of plasmid DNA.
Collection of samples
Mice were killed by cervical dislocation. TA muscles were excised post mortem and either snap-frozen in liquid nitrogen for analysis by ELISA, or mounted on a cork block, embedded in Cryo-M-Bed (Bright, Huntingdon, UK) and snap-frozen in liquid-nitrogen-cooled isopentane for histological analysis. The frozen muscles were stored at À701C. To analyse transfection efficiency and muscle damage, 10 mm cryostat sections were cut at a minimum of 10 evenly spaced levels throughout each muscle and lifted onto APES-coated slides. Slides were stored at À701C after air-drying. Histology X-gal staining for b-galactosidase was carried out as follows: cryostat sections were fixed in 2% formaldehyde in phosphate-buffered saline (PBS) for 5 min and then washed in PBS. Slides were incubated overnight at 371C in X-gal staining solution (1 mM X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 in PBS). Sections were counterstained in 2% alcoholic eosin, dehydrated through graded alcohols, cleared in xylene and mounted in DPX.
Immunocytochemistry for the detection of dystrophin was carried out as follows: Cryostat sections were airdried for 30 min at room temperature, and blocked with avidin/biotin blocking agent (Vector Laboratories, Southgate, UK) and 5% milk in PBST. A rabbit polyclonal antibody directed to the last 17 amino acids of the carboxy terminal region of dystrophin (Dys C3750, made commercially by Cymbus Biotechnology, Chandlers Ford, UK) was used at 1:1000. Bound antibody was detected using a biotinylated secondary antibody followed by HRP-conjugated streptavidin-biotin complex and DAB.
Haematoxylin and eosin staining was carried out in order to assess cell morphology and inflammatory infiltrate.
Sirius red and picric acid staining was carried out in order to assess the levels of connective tissue within a particular muscle. Staining was carried out as follows: Muscle sections were removed from storage at À701C and allowed to come to room temperature. Muscle sections were soaked in tap water for 2 min and then immersed in the sirius red/picric acid staining solution (50 ml saturated aqueous picric acid, 9 ml 1% aqueous sirius red solution, 50 ml distilled water) for 3 min. Excess staining solution was removed from the slides by blotting them dry with tissue paper. Muscle sections were immediately dehydrated through three changes of 100% IMS (1 min for each wash) and cleared in xylene and mounted in DPX.
A Leica DMLB research microscope (Leica, Wetzler, Germany) with a colour JVC Ky-F55B 3-CCD camera was used to import images to a computer. Images were captured using SnapperTool version 2.04 software from DataCell Ltd, Maidenhead, UK. Further image orientation was carried out using Adobe Photoshop version 5.0.2 (Polaroid, USA).
b-galactosidase ELISA
For analysis of total b-galactosidase expression, a tibialis anterior muscle was homogenized in a microfuge tube with a micropestle in 100 ml of lysis buffer (from bgalactosidase ELISA kit, Boehringer, Lewes, UK) together with a cocktail of protease inhibitors (50 mg/ml antipain, 10 mg/ml aprotinin, and 0.5 mg/ml leupeptin). The volume was increased to a total of 400 ml and the tissue subjected to three rounds of freeze-thaw cycles. After mixing thoroughly, the solution was spun at 13 000 rpm for 10 min to pellet all insoluble material. Supernatants were stored at À701C until assayed. For each assay equal volumes of supernatant were diluted to 200 ml and assayed using the b-galactosidase ELISA kit as per the manufacturer's instructions.
Analysis
Transverse muscle sections were stained for b-galactosidase expression and were analysed using Sigma Scan Pro 5.0 to establish the maximum area transfected within a transverse muscle section of any one muscle. When assessing transfection levels following dystrophin plasmid gene transfer, the maximum number of positive fibres were counted within a transverse muscle section, counts included revertant fibres. Statistical analysis was carried out by one-way ANOVA followed by multiple paired comparison, or by t-test where specified. Groups were considered significantly different when Po0.05. Statistical tests were conducted using Sigma-Stat (SPSS, Birmingham, UK). of the BTX electroporator and electrodes. This work was funded by the Medical Research Council of Great Britain, the Muscular Dystrophy Campaign and the Wellcome Trust.
